JP2015525768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015525768A5 JP2015525768A5 JP2015521997A JP2015521997A JP2015525768A5 JP 2015525768 A5 JP2015525768 A5 JP 2015525768A5 JP 2015521997 A JP2015521997 A JP 2015521997A JP 2015521997 A JP2015521997 A JP 2015521997A JP 2015525768 A5 JP2015525768 A5 JP 2015525768A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence number
- sequence
- disease
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 8
- 230000003110 anti-inflammatory effect Effects 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000004881 Amebiasis Diseases 0.000 claims 1
- 206010001980 Amoebiasis Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000031729 Bacteremia Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 206010007134 Candida infections Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008088 Cerebral artery embolism Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009895 Colitis ischaemic Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010016228 Fasciitis Diseases 0.000 claims 1
- 201000006353 Filariasis Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000024781 Immune Complex disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 108010017842 Telomerase Proteins 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 208000025609 Urogenital disease Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000003984 candidiasis Diseases 0.000 claims 1
- 230000007910 cell fusion Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000003167 cholangitis Diseases 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 230000002327 eosinophilic effect Effects 0.000 claims 1
- 208000001606 epiglottitis Diseases 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000021760 high fever Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000010849 intracranial embolism Diseases 0.000 claims 1
- 201000008222 ischemic colitis Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 208000008494 pericarditis Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010035653 pneumoconiosis Diseases 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 208000013223 septicemia Diseases 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000005060 thrombophlebitis Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 238000009423 ventilation Methods 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2012-0079096 | 2012-07-20 | ||
| KR1020120079096A KR20140012385A (ko) | 2012-07-20 | 2012-07-20 | 항염증 활성을 갖는 펩티드 및 이를 포함하는 염증질환 치료용 조성물 |
| KR10-2012-0089162 | 2012-08-14 | ||
| KR1020120089162A KR20140022698A (ko) | 2012-08-14 | 2012-08-14 | 텔로머라제 펩티드를 포함하는 염증 예방 또는 억제용 조성물 |
| KR10-2012-0089161 | 2012-08-14 | ||
| KR1020120089167A KR20140022699A (ko) | 2012-08-14 | 2012-08-14 | 텔로머라제 펩티드를 포함하는 염증 예방 또는 억제용 조성물 |
| KR10-2012-0089167 | 2012-08-14 | ||
| KR20120089161 | 2012-08-14 | ||
| KR10-2012-0104207 | 2012-09-19 | ||
| KR20120104144 | 2012-09-19 | ||
| KR10-2012-0104144 | 2012-09-19 | ||
| KR20120104207 | 2012-09-19 | ||
| PCT/EP2013/055326 WO2014012683A1 (en) | 2012-07-20 | 2013-03-15 | Anti-inflammatory peptides and composition comprising the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017077422A Division JP6514259B2 (ja) | 2012-07-20 | 2017-04-10 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015525768A JP2015525768A (ja) | 2015-09-07 |
| JP2015525768A5 true JP2015525768A5 (https=) | 2016-05-12 |
| JP6352911B2 JP6352911B2 (ja) | 2018-07-04 |
Family
ID=47882177
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521997A Active JP6352911B2 (ja) | 2012-07-20 | 2013-03-15 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2017077422A Active JP6514259B2 (ja) | 2012-07-20 | 2017-04-10 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2019075635A Active JP6788062B2 (ja) | 2012-07-20 | 2019-04-11 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2020181780A Active JP7128246B2 (ja) | 2012-07-20 | 2020-10-29 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2022130519A Active JP7440581B2 (ja) | 2012-07-20 | 2022-08-18 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2024021407A Active JP7741218B2 (ja) | 2012-07-20 | 2024-02-15 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017077422A Active JP6514259B2 (ja) | 2012-07-20 | 2017-04-10 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2019075635A Active JP6788062B2 (ja) | 2012-07-20 | 2019-04-11 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2020181780A Active JP7128246B2 (ja) | 2012-07-20 | 2020-10-29 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2022130519A Active JP7440581B2 (ja) | 2012-07-20 | 2022-08-18 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2024021407A Active JP7741218B2 (ja) | 2012-07-20 | 2024-02-15 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US20150125438A1 (https=) |
| EP (3) | EP2875042B1 (https=) |
| JP (6) | JP6352911B2 (https=) |
| KR (2) | KR20150031413A (https=) |
| CN (3) | CN104470947B (https=) |
| ES (3) | ES3055196T3 (https=) |
| TW (6) | TWI836435B (https=) |
| WO (1) | WO2014012683A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9320058D0 (en) | 1993-09-29 | 1993-11-17 | Gillette Co | Savety razors |
| WO2013167298A1 (en) | 2012-05-11 | 2013-11-14 | Kael-Gemvax Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
| ES2981865T3 (es) | 2012-07-11 | 2024-10-10 | Gemvax & Kael Co Ltd | Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo |
| US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| ES2999332T3 (en) | 2012-09-19 | 2025-02-25 | Gemvax & Kael Co Ltd | Cell penetrating peptide, conjugate comprising the same, and composition comprising conjugate |
| WO2014046478A1 (ko) | 2012-09-19 | 2014-03-27 | 주식회사 카엘젬백스 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
| ES2926463T3 (es) | 2013-03-15 | 2022-10-26 | Promega Corp | Activación de la bioluminiscencia mediante complementación estructural |
| RU2677277C2 (ru) | 2013-06-07 | 2019-01-16 | Джемвакс Энд Каэл Ко., Лтд. | Биологические маркеры, которые могут быть использованы в иммунотерапии рака |
| JP6495899B2 (ja) | 2013-06-21 | 2019-04-03 | ジェムバックス アンド カエル カンパニー，リミティド | ホルモン分泌調節剤、及びそれを含む組成物 |
| CN105531284B (zh) * | 2013-07-12 | 2021-03-23 | 珍白斯凯尔有限公司 | 细胞穿透肽和包含其的缀合物 |
| KR102359396B1 (ko) | 2013-11-22 | 2022-02-08 | 주식회사 젬백스앤카엘 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| KR102314231B1 (ko) | 2013-12-17 | 2021-10-19 | 주식회사 젬백스앤카엘 | 전립선 암 치료용 조성물 |
| WO2015156649A1 (ko) * | 2014-04-11 | 2015-10-15 | 주식회사 젬백스앤카엘 | 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| JP6466971B2 (ja) * | 2014-04-30 | 2019-02-06 | ジェムバックス アンド カエル カンパニー，リミティド | 臓器、組織又は細胞移植用組成物、キット及び移植方法 |
| WO2016042131A1 (en) * | 2014-09-18 | 2016-03-24 | The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth Near Dublin | Use of inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| KR102636129B1 (ko) | 2015-02-27 | 2024-02-14 | 주식회사 젬백스앤카엘 | 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물 |
| KR101662438B1 (ko) * | 2015-04-07 | 2016-10-04 | 가톨릭대학교 산학협력단 | X형 구조의 dna를 유효성분으로 포함하는 아토피 피부염 예방 또는 치료용 조성물 |
| KR101734529B1 (ko) | 2015-05-08 | 2017-05-11 | 건국대학교 산학협력단 | 패혈증 치료제의 스크리닝 방법 및 패혈증 치료용 약학 조성물 |
| KR20250073577A (ko) | 2015-05-26 | 2025-05-27 | 주식회사 젬백스앤카엘 | 신규 펩티드 및 이를 포함한 조성물 |
| KR102638286B1 (ko) * | 2015-07-02 | 2024-02-20 | 주식회사 젬백스앤카엘 | 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
| CA2996951C (en) * | 2015-08-28 | 2024-05-07 | The Medical College Of Wisconsin, Inc. | Peptide inhibitors of telomerase translocation and therapeutic uses thereof |
| CN108348167B (zh) * | 2015-09-09 | 2022-06-03 | 普梭梅根公司 | 用于脑-颅面健康相关病症的源自微生物群系的诊断及治疗方法和系统 |
| US10898540B2 (en) | 2016-04-07 | 2021-01-26 | Gem Vax & KAEL Co., Ltd. | Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same |
| KR101831888B1 (ko) * | 2016-04-15 | 2018-04-16 | (주)케어젠 | 항염증 활성을 갖는 펩타이드 및 이의 용도 |
| KR101887577B1 (ko) * | 2016-10-19 | 2018-09-10 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
| JP7213811B2 (ja) * | 2016-12-22 | 2023-01-27 | ウニヴェルシテ・ドゥ・モンペリエ | 新規なステープルペプチドおよびその使用 |
| JP6601849B2 (ja) * | 2017-08-21 | 2019-11-06 | 株式会社大一商会 | 遊技機 |
| JP6601848B2 (ja) * | 2017-08-21 | 2019-11-06 | 株式会社大一商会 | 遊技機 |
| KR102092843B1 (ko) * | 2018-08-30 | 2020-03-24 | 충남대학교 산학협력단 | 암 예방 또는 치료용 펩타이드 및 이의 용도 |
| KR102274658B1 (ko) * | 2018-11-16 | 2021-07-09 | 주식회사 카인사이언스 | 염증성 피부질환 치료용 펩타이드 및 이의 용도 |
| KR102032945B1 (ko) * | 2018-12-03 | 2019-10-16 | 순천대학교 산학협력단 | 항염증 활성을 나타내는 펩타이드 및 이를 유효성분으로 포함하는 항염증용 조성물 |
| KR102146937B1 (ko) * | 2018-12-11 | 2020-08-21 | 대한민국 | 왕사마귀로부터 유래된 테노데라신-1 펩타이드, 이를 유효성분으로 포함하는 항균, 항진균 또는 항염증용 조성물 |
| KR102266613B1 (ko) * | 2020-09-21 | 2021-06-18 | 자안바이오 주식회사 | 항염증 활성을 갖는 신규한 펩티드 및 이의 용도 |
| WO2022167656A1 (en) * | 2021-02-08 | 2022-08-11 | Bacoba Ag | Treatment of skin disorders |
| KR20230156265A (ko) * | 2022-05-03 | 2023-11-14 | 한국생명공학연구원 | 신규 펩타이드 및 이의 항염 및 재생 용도 |
| KR102827929B1 (ko) * | 2023-01-26 | 2025-07-09 | ㈜에빅스젠 | 신규한 뇌 질환 치료제 및 이의 용도 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1523965A (en) * | 1976-03-19 | 1978-09-06 | Ici Ltd | Pharmaceutical compositions containing steroids |
| DE4330664A1 (de) * | 1993-09-10 | 1995-03-16 | Beiersdorf Ag | Verwendungen von Pflanzenölen |
| AU696702B2 (en) * | 1994-07-07 | 1998-09-17 | Geron Corporation | Mammalian telomerase |
| CN1080260C (zh) * | 1996-06-25 | 2002-03-06 | 美国辉瑞有限公司 | 取代的吲哚衍生物以及它们作为iv型磷酸二酯酶(pde)和肿瘤坏死因子(tnf)抑制剂的用途 |
| EP0932686A2 (en) * | 1996-10-01 | 1999-08-04 | Geron Corporation | Telomerase reverse transcriptase |
| US6610839B1 (en) * | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
| KR100581990B1 (ko) * | 1997-07-01 | 2006-05-23 | 캄비아 바이오시스템즈 엘엘씨 | 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도 |
| US7030211B1 (en) * | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
| KR20040041575A (ko) * | 2001-07-31 | 2004-05-17 | 칼 페터 쇠더스트룀 | 면역반응의 모듈화 조성물 및 모듈화 방법 |
| US20060127894A1 (en) * | 2001-08-08 | 2006-06-15 | Incyte Corporation | Protein associated with cell growth, differentiation, and death |
| US8492438B2 (en) * | 2002-04-26 | 2013-07-23 | Asan Laboratories Company (Cayman), Limited | Treatment skin disorders |
| EP1625220A2 (en) * | 2003-05-01 | 2006-02-15 | MUSC Foundation For Research Development | An autologous upregulation mechanism allowing optimized cell type-specific and regulated gene expression cells |
| CN101011571A (zh) * | 2006-03-13 | 2007-08-08 | 上海交通大学医学院 | GADD45 β 蛋白及其抑制剂在类风湿关节炎中的应用 |
| CA2665816C (en) * | 2006-09-21 | 2016-07-12 | Vaxil Biotherapeutics Ltd. | Antigen specific multi epitope vaccines |
| EP2076531B1 (en) * | 2006-10-12 | 2011-11-23 | Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. | Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof |
| AU2008252628A1 (en) | 2007-05-18 | 2008-11-27 | Inhibox Ltd. | Bicyclosulfonyl acid (BCSA) compounds and their use as therapeutic agents |
| WO2009025871A1 (en) * | 2007-08-23 | 2009-02-26 | University Of Medicine And Dentistry Of Nj | Telomerase reverse transcriptase variant |
| GB2455539B (en) | 2007-12-12 | 2012-01-18 | Cambridge Entpr Ltd | Anti-inflammatory compositions and combinations |
| ES2602453T3 (es) * | 2008-06-16 | 2017-02-21 | Mediolanum Farmaceutici S.P.A. | Inmunoterapia antitumoral |
| US8252282B2 (en) * | 2008-06-19 | 2012-08-28 | University Of Medicine & Dentistry Of New Jersey | Nuclear telomerase reverse transcriptase variant |
| KR20110060940A (ko) | 2008-09-22 | 2011-06-08 | 닛신 파마 가부시키가이샤 | 항염증성 펩티드 |
| WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| EP2536830B1 (en) * | 2010-02-16 | 2019-07-17 | Ultimovacs AS | Polypeptides |
| KR101284772B1 (ko) | 2011-05-24 | 2013-07-17 | 정종문 | 항염증, 진통효과를 가지는 기능성 식품 조성물 |
| KR20120133661A (ko) | 2011-05-31 | 2012-12-11 | 주식회사 바이오포트코리아 | 아스타잔틴을 포함하는 항염증제 |
| WO2013167298A1 (en) | 2012-05-11 | 2013-11-14 | Kael-Gemvax Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
| US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| ES2999332T3 (en) | 2012-09-19 | 2025-02-25 | Gemvax & Kael Co Ltd | Cell penetrating peptide, conjugate comprising the same, and composition comprising conjugate |
| WO2014046478A1 (ko) | 2012-09-19 | 2014-03-27 | 주식회사 카엘젬백스 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
| JP6510410B2 (ja) | 2012-09-19 | 2019-05-08 | ジェムバックス アンド カエル カンパニー，リミティド | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| RU2677277C2 (ru) * | 2013-06-07 | 2019-01-16 | Джемвакс Энд Каэл Ко., Лтд. | Биологические маркеры, которые могут быть использованы в иммунотерапии рака |
| CN105531284B (zh) | 2013-07-12 | 2021-03-23 | 珍白斯凯尔有限公司 | 细胞穿透肽和包含其的缀合物 |
| KR20250073577A (ko) | 2015-05-26 | 2025-05-27 | 주식회사 젬백스앤카엘 | 신규 펩티드 및 이를 포함한 조성물 |
| US20170112941A1 (en) | 2015-10-13 | 2017-04-27 | Symic Ip, Llc | Ve-cadherin binding bioconjugate |
-
2013
- 2013-03-05 US US14/400,322 patent/US20150125438A1/en not_active Abandoned
- 2013-03-15 EP EP13709221.9A patent/EP2875042B1/en active Active
- 2013-03-15 CN CN201380038045.1A patent/CN104470947B/zh active Active
- 2013-03-15 ES ES21162575T patent/ES3055196T3/es active Active
- 2013-03-15 CN CN202311502816.XA patent/CN117551631A/zh active Pending
- 2013-03-15 EP EP18187426.4A patent/EP3428182B1/en active Active
- 2013-03-15 WO PCT/EP2013/055326 patent/WO2014012683A1/en not_active Ceased
- 2013-03-15 KR KR1020147034319A patent/KR20150031413A/ko not_active Ceased
- 2013-03-15 ES ES18187426T patent/ES2871899T3/es active Active
- 2013-03-15 EP EP21162575.1A patent/EP3896078B1/en active Active
- 2013-03-15 CN CN201910110866.0A patent/CN109777791B/zh active Active
- 2013-03-15 JP JP2015521997A patent/JP6352911B2/ja active Active
- 2013-03-15 KR KR1020207019525A patent/KR102302392B1/ko active Active
- 2013-03-15 ES ES13709221T patent/ES2693321T3/es active Active
- 2013-05-01 TW TW111118818A patent/TWI836435B/zh active
- 2013-05-01 TW TW109115548A patent/TWI779287B/zh active
- 2013-05-01 TW TW108101145A patent/TWI700290B/zh active
- 2013-05-01 TW TW102115615A patent/TWI658141B/zh active
- 2013-05-01 TW TW106121753A patent/TWI647311B/zh active
- 2013-05-01 TW TW113100053A patent/TW202417473A/zh unknown
-
2017
- 2017-04-05 US US15/479,746 patent/US20170275603A1/en not_active Abandoned
- 2017-04-10 JP JP2017077422A patent/JP6514259B2/ja active Active
-
2019
- 2019-04-11 JP JP2019075635A patent/JP6788062B2/ja active Active
-
2020
- 2020-01-17 US US16/746,018 patent/US20200140832A1/en not_active Abandoned
- 2020-03-13 US US16/818,001 patent/US11098294B2/en active Active
- 2020-10-29 JP JP2020181780A patent/JP7128246B2/ja active Active
-
2021
- 2021-07-30 US US17/389,671 patent/US11905536B2/en active Active
-
2022
- 2022-08-18 JP JP2022130519A patent/JP7440581B2/ja active Active
-
2024
- 2024-01-12 US US18/411,838 patent/US20240158768A1/en active Pending
- 2024-02-15 JP JP2024021407A patent/JP7741218B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015525768A5 (https=) | ||
| JP2015523323A5 (https=) | ||
| JP2015521039A5 (https=) | ||
| JP2015517489A5 (https=) | ||
| JP2019530462A5 (https=) | ||
| Ibañez et al. | Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection | |
| JP2016128513A5 (https=) | ||
| PH12018501912A1 (en) | Vaccine against rsv | |
| JP2016515524A5 (https=) | ||
| JP2015501656A5 (https=) | ||
| JP2015529678A5 (https=) | ||
| SI2699601T1 (en) | PROTITOLIC POLYPETIDES AS THE CD40 ANTAGONISTS | |
| JP2012115277A5 (https=) | ||
| GB201206559D0 (en) | Polypeptide | |
| FI3526323T3 (fi) | Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja | |
| JP2016513471A5 (https=) | ||
| JP2013539454A5 (https=) | ||
| JP2015212284A5 (https=) | ||
| JP2013172743A5 (https=) | ||
| Chong et al. | Two MT hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK | |
| JP2011528897A5 (https=) | ||
| IL276158B1 (en) | Methods and compositions for treatment of angiogenic disorders using anti-vegf agents | |
| JPWO2019156137A5 (https=) | ||
| JP2013531993A5 (https=) | ||
| JP2016508503A5 (https=) |